Free tool
FAERS Monitor: Focinvez
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216686 or its brand name (Focinvez, Fosaprepitant Dimeglumine). Reports on generic versions are filed under their own applications.
Reports
789
Serious
707
90% of reports
Hospitalization
366
Death reported
131
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea107
- alopecia88
- off label use78
- pyrexia76
- fatigue75
- infusion related reaction72
- nausea72
- hypersensitivity69
- rash69
- impaired healing67
- infection67
- pain65
- folliculitis64
- hepatic enzyme increased64
- ill-defined disorder64
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 2 |
| 2012 | 89 |
| 2013 | 35 |
| 2014 | 26 |
| 2015 | 25 |
| 2016 | 13 |
| 2017 | 14 |
| 2018 | 45 |
| 2019 | 42 |
| 2020 | 37 |
| 2021 | 60 |
| 2022 | 75 |
| 2023 | 52 |
| 2024 | 77 |
| 2025 | 113 |
| 2026 | 84 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,370 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| folliculitisSignal | 64 | 163.7 | 129.3 | 10,130 |
| impaired healingSignal | 67 | 54.5 | 43.3 | 3,465 |
| infusion related reactionSignal | 72 | 29.0 | 23.3 | 1,922 |
| ill-defined disorderSignal | 64 | 28.1 | 22.2 | 1,649 |
| hepatic enzyme increasedSignal | 64 | 25.0 | 19.8 | 1,457 |
| infectionSignal | 67 | 12.3 | 9.8 | 692 |
| alopeciaSignal | 88 | 12.0 | 9.8 | 880 |
| hypersensitivitySignal | 69 | 9.9 | 7.9 | 549 |
| pyrexiaSignal | 76 | 5.9 | 4.7 | 306 |
| dyspnoeaSignal | 107 | 5.0 | 4.2 | 352 |
| rashSignal | 69 | 4.2 | 3.4 | 170 |
| painSignal | 65 | 2.8 | 2.2 | 77 |
| fatigueSignal | 75 | 2.6 | 2.1 | 73 |
| nauseaSignal | 72 | 2.4 | 1.9 | 61 |
| off label useSignal | 78 | 2.4 | 1.9 | 63 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.